EOCN on Nasdaq

Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a pharmaceutical preparations company, listed on Nasdaq (EOCN).1

Price unavailable

Last updated Oct 20, 2026.

Overview

-$10.3MNet income, fiscal 20252

Compare with Magenta Therapeutics, Cocrystal Pharma, Inc. or Korsana Biosciences, Inc., or pick any stock.

  • TickerEOCN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business addressC/O Meitar Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, L3 52506083
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-65.2%Return on equity4
-$26.3MFree cash flow5

Financial statements

Revenue6$0 in 2020
0$1.0M$2.0M$3.0M2018: $2.0M$2.0M20182019: $0$020192020: $0$02020
Operating income6-$30.2M in 2020+182% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$10.7M-$10.7M20182019: -$22.4M-$22.4M2019+109%2020: -$30.2M-$30.2M2020+35%
Net income675-$28.8M in 2020+192% since 2018
-$30.0M-$20.0M-$10.0M02018: -$9.9M-$9.9M20182019: -$20.5M-$20.5M2019+108%2020: -$28.8M-$28.8M2020+41%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Research and development expenses$4.9M$3.0M$3.6M
General and administrative expenses$3.6M$3.3M$3.9M
Total operating loss$8.5M$6.3M$7.5M
Financial income, net-$741.0K-$516.0K-$580.0K
Financial expenses related to SEPA$79.0K$610.0K
Impairment on associate and associated loan$2.5M$1.1M
Net loss$10.3M$7.5M$6.9M
Basic, net loss per share$2.39$8.08$30.00
Diluted, net loss per share$2.39$8.08$30.00
Weighted average number of shares outstanding used in computing net loss per share, basic4.3M shares930.8K shares230.8K shares
Weighted average number of shares outstanding used in computing net loss per share, diluted4.3M shares930.8K shares230.8K shares

Compare Galmed Pharmaceuticals Ltd. with another company

Corporate structure

Galmed Pharmaceuticals Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Galmed Pharmaceuticals Ltd.

  • CVI Investments, Inc. Filed SCHEDULE 13G/A on Galmed Pharmaceuticals Ltd., latest Nov 7, 2025 (5 filings since Jul 21, 2023)
  • Allen Baharaff Filed SCHEDULE 13G/A on Galmed Pharmaceuticals Ltd., latest Feb 18, 2025 (4 filings since Feb 11, 2022)
  • Masaya Otsuka Filed SC 13G/A on Galmed Pharmaceuticals Ltd., latest Sep 20, 2024 (2 filings since Sep 20, 2024)
  • BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Galmed Pharmaceuticals Ltd., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • Nantahala Capital Management, LLC Filed SC 13G/A on Galmed Pharmaceuticals Ltd., latest Feb 14, 2022
  • IBEX INVESTORS LLC Filed SC 13G/A on Galmed Pharmaceuticals Ltd., latest Jan 27, 2022
  • Galmed Pharmaceuticals Ltd. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Galmed Pharmaceuticals Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$737.0K9 Dec 31, 2024$737.0K9 Dec 31, 20230%
Furniture and fixtures$55.0K9 Dec 31, 2024$55.0K9 Dec 31, 20230%
Computer equipment and software$75.0K9 Dec 31, 2024$75.0K9 Dec 31, 20230%
Leasehold improvements$236.0K9 Dec 31, 2024$235.0K9 Dec 31, 2023+0.4%
Property and equipment, before depreciation$1.1M9 Dec 31, 2024$1.1M9 Dec 31, 2023+0.1%
Accumulated depreciation$1.1M9 Dec 31, 2024$1.0M9 Dec 31, 2023+8.2%

Real estate and locations

ItemLatestA year beforeChange
Area of land590 sq ft9 Dec 31, 2024590 sq ft4 Dec 31, 20230%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.0M2 Dec 31, 2025$4.7M2 Dec 31, 2024−14.3%
Marketable securities, current$7.0M2 Dec 31, 2025$7.2M2 Dec 31, 2024−2.2%
Debt securities available for sale$7.0M2 Dec 31, 2025$7.2M2 Dec 31, 2024−2.2%

Leadership

Who has led Galmed Pharmaceuticals Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Allen Baharaff2026–now

Chief operating officer

  1. Guy Nehemya2026–now
Board members and other officers (7)

Timeline

  1. Mar 18, 2026New chief executive Allen Baharaff becomes CEO10

Calendar

Coming up

  1. Nov 25, 2026Reports results for the quarter ending Sep/202618

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

183 filings to the SEC since October 2021: 5 annual reports, 9 insider forms, 15 large holders, 154 other. The latest 20:

  1. Sep 9, 20266-K EDGAR
  2. Sep 8, 20266-K EDGAR
  3. Sep 3, 2026EFFECT EDGAR
  4. Sep 3, 20266-K EDGAR
  5. Sep 2, 2026POS AM EDGAR
  6. Sep 2, 20266-K EDGAR
  7. Sep 2, 20266-K EDGAR
  8. Aug 19, 20266-K/A EDGAR
  9. Aug 19, 20266-K EDGAR
  10. Aug 17, 20266-K EDGAR
  11. Aug 14, 20266-K EDGAR
  12. Jul 31, 20266-K EDGAR
  13. Jul 29, 20266-K EDGAR
  14. Jul 28, 20266-K EDGAR
  15. Jul 22, 20266-K EDGAR
  16. Jul 16, 20266-K EDGAR
  17. Jul 8, 20266-K EDGAR
  18. Jun 22, 2026424B3 EDGAR
  19. Jun 22, 20266-K EDGAR
  20. Jun 8, 2026POS EX EDGAR

The 183 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Galmed Pharmaceuticals Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGalmed Pharmaceuticals Ltd.1
  • CIK0001595353
  • Employer ID (EIN)98-11472331
  • Filer statusNon-accelerated filer not an emerging growth company; a shell company25
  • Incorporated inIsrael25
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressC/O Meitar Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, L3 52506081
  • Phone972369384481
  • Shares outstanding6,581,390 shares as of Dec 31, 202525
  • AuditorBrightman Almagor Zohar & Co., Tel Aviv, Israel PCAOB ID 1197; no auditor attestation of internal control over financial reporting25
  • On EDGAR sinceDec 31, 20131
  • Filings381 in all: 6-K (225), SC 13G/A (25), EFFECT (15), CORRESP (13), 20-F (12), 424B5 (10), UPLOAD (10), 3 (9)1
    All 30 form types

    SC 13G (8), POS AM (7), 424B3 (5), F-1 (5), F-1/A (5), F-3 (4), S-8 (4), 20-F/A (3), 6-K/A (3), SCHEDULE 13G/A (3), 424B4 (2), FWP (2), POS EX (2), 424A (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), D (1), DRS (1), DRSLTR (1), F-1MEF (1), S-8 POS (1)

  • Latest filingsAnnual report (20-F) Mar 31, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary shares, par value NIS 1.80 per shareGLMDNasdaq

From the cover page of the 20-F filed Mar 31, 2026 (Section 12(b) of the Exchange Act).25

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25